Staying Ahead of the Changing HPV Testing Landscape: A 360 Degree Review

In 2020, American Cancer Society released an updated cervical cancer screening guideline calling for primary human papillomavirus (HPV) screening as the preferred strategy. Utility of HPV primary screening enables risk stratification by genotyping which leads to more effective triage and personalized care for patients. This session will review the results from the Alinity m HR HPV* clinical trial and how this test may be utilized in clinical practice. We will also review the workflow efficiencies that can be achieved when introducing an automated pre-analytical system** to HPV testing.

* Alinity m HR HPV assay is pending FDA review and not commercially available in the United States.
** Alinity mp is under development and not commercially available.